NEW YORK (GenomeWeb News) – Agilent Technologies today said that it will collaborate with sera prognostics on the development of proteomic assays for early prediction of pregnancy complications.
The firms plan to develop high-throughput workflows for sample preparation and mass-spectrometry analysis. Salt Lake City-based Sera Prognostics said that it has purchased multiple Agilent 1290 Infinity ultra high-performance liquid chromatography systems, 6490 iFunnel triple quadrupole mass spectrometry systems, and 1260 Infinity LC systems with ultraviolet detectors, as part of the alliance.
Sera Prognostics is currently developing a proteomic-based test for the early prediction of preterm birth risk.
"Our partnership with Agilent provides Sera with access to advanced and innovative technologies designed to deliver on the promise of personalized medicine," Sera Prognostics Chairman and CEO Gregory Critchfield said in a statement.
Financial and other terms of the alliance were not disclosed.